BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28830135)

  • 21. Predictive factors in the differential diagnosis of benign and malignant causes in patients undergoing endoscopic retrograde cholangiopancreatography for extrahepatic cholestasis.
    Yildirim O; Erdogan MA
    Eur Rev Med Pharmacol Sci; 2023 Dec; 27(23):11457-11463. PubMed ID: 38095393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The usefulness of adding p53 immunocytochemistry to bile drainage cytology for the diagnosis of malignant biliary strictures.
    Yeo MK; Kim KH; Lee YM; Lee BS; Choi SY
    Diagn Cytopathol; 2017 Jul; 45(7):592-597. PubMed ID: 28411396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of preoperative biliary drainage on liver function changes in patients with malignant obstructive jaundice in the low bile duct before and after pancreaticoduodenectomy].
    Chen D; Liang LJ; Peng BG; Zhou Q; Li SQ; Tang D; Huang L; Huang JF
    Ai Zheng; 2008 Jan; 27(1):78-82. PubMed ID: 18184470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction.
    Sasahira N; Hamada T; Togawa O; Yamamoto R; Iwai T; Tamada K; Kawaguchi Y; Shimura K; Koike T; Yoshida Y; Sugimori K; Ryozawa S; Kakimoto T; Nishikawa K; Kitamura K; Imamura T; Mizuide M; Toda N; Maetani I; Sakai Y; Itoi T; Nagahama M; Nakai Y; Isayama H
    World J Gastroenterol; 2016 Apr; 22(14):3793-802. PubMed ID: 27076764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum nitric oxide levels in patients with benign and malignant biliary disease: a prospective single center study.
    Beyazit Y; Sayilir A; Koklu S; Torun S; Suvak B; Tas A; Purnak T; Kalkan IH; Yesil Y; Ibis M
    J Clin Gastroenterol; 2013 Mar; 47(3):258-63. PubMed ID: 23059408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer.
    Chen WM; Wei KL; Chen YS; Chang PJ; Tung SY; Chang TS; Huang HC; Shen CH; Hsieh YY; Wu CS
    World J Surg Oncol; 2016 May; 14():140. PubMed ID: 27142076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multistep cytological approach for patients with jaundice and biliary strictures of indeterminate origin.
    Boldorini R; Paganotti A; Andorno S; Orlando S; Mercalli F; Orsello M; Ballarè M; Magnani C; Sartori M
    J Clin Pathol; 2015 Apr; 68(4):283-7. PubMed ID: 25681513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of percutaneous transhepatic biliary drainage on renal function in patients with obstructive jaundice.
    Parıldar Z; Çınar C; Barutçuoğlu B; Başol G; Parıldar M
    Diagn Interv Radiol; 2011 Mar; 17(1):74-9. PubMed ID: 20690079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma.
    Sugiyama G; Okabe Y; Ishida Y; Saitou F; Kawahara R; Ishikawa H; Horiuchi H; Kinoshita H; Tsuruta O; Sata M
    World J Gastroenterol; 2014 Jun; 20(22):6968-73. PubMed ID: 24944490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of the mucin filled bile duct. A complication of intraductal papillary mucinous tumor of the pancreas.
    Patel A; Lambiase L; Decarli A; Fazel A
    JOP; 2005 May; 6(3):255-9. PubMed ID: 15883476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated serum level of carbohydrate antigen 19-9 in benign biliary stricture diseases can reduce its value as a tumor marker.
    Lin MS; Huang JX; Yu H
    Int J Clin Exp Med; 2014; 7(3):744-50. PubMed ID: 24753772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bile levels of carcino-embryonic antigen in patients with hepatopancreatobiliary disease.
    Buffet C; Fourré C; Altman C; Prat F; Fritsch J; Choury A; Briantais MJ; Desgrez A; Etienne JP
    Eur J Gastroenterol Hepatol; 1996 Feb; 8(2):131-4. PubMed ID: 8723416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CA19-9 has no value as a tumor marker in obstructive jaundice].
    Peterli R; Meyer-Wyss B; Herzog U; Tondelli P
    Schweiz Med Wochenschr; 1999 Jan; 129(3):77-9. PubMed ID: 10065510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Endoscopic Ultrasonography Guided Biliary Drainage and Percutaneous Transhepatic Biliary Drainage in the Management of Malignant Obstructive Jaundice After Failed ERCP.
    Huang P; Zhang H; Zhang XF; Lv W; Lou S
    Surg Laparosc Endosc Percutan Tech; 2017 Dec; 27(6):e127-e131. PubMed ID: 29206804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
    Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
    Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and radiological predictors of malignant biliary strictures.
    Al-Mofleh IA; Aljebreen AM; Al-Amri SM; Al-Rashed RS; Al-Faleh FZ; Al-Freihi HM; Abdo AA; Isnani AC
    World J Gastroenterol; 2004 May; 10(10):1504-7. PubMed ID: 15133862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice.
    Duraker N; Hot S; Polat Y; Höbek A; Gençler N; Urhan N
    J Surg Oncol; 2007 Feb; 95(2):142-7. PubMed ID: 17262731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporary placement of a covered duodenal stent can avoid riskier anterograde biliary drainage when ERCP for obstructive jaundice fails due to duodenal invasion.
    Goutorbe F; Rouquette O; Mulliez A; Scanzi J; Goutte M; Dapoigny M; Abergel A; Poincloux L
    Surg Endosc; 2017 Feb; 31(2):625-631. PubMed ID: 27324333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels.
    Jin X; Wu Y
    Afr Health Sci; 2015 Mar; 15(1):123-30. PubMed ID: 25834540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.